Cargando…

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

BACKGROUND AND AIMS: Ustekinumab is approved for the treatment of Crohn’s disease [CD]. Systematically registered prospective real-world data are scarce. We therefore aimed to study the effectiveness, safety and usage of ustekinumab for CD in everyday practice. METHODS: We prospectively enrolled CD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biemans, Vince B C, van der Meulen - de Jong, Andrea E, van der Woude, Christine J, Löwenberg, Mark, Dijkstra, Gerard, Oldenburg, Bas, de Boer, Nanne K H, van der Marel, Sander, Bodelier, Alexander G L, Jansen, Jeroen M, Haans, Jeoffrey J L, Theeuwen, Rosaline, de Jong, Dirk, Pierik, Marie J, Hoentjen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142409/ https://www.ncbi.nlm.nih.gov/pubmed/31219157 http://dx.doi.org/10.1093/ecco-jcc/jjz119

Ejemplares similares

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes
por: Voskuil, M D, et al.
Publicado: (2020)

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn’s disease
por: Barendregt, Jessika, et al.
Publicado: (2016)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
por: Beelen, Evelien M J, et al.
Publicado: (2023)

Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study
por: Goetgebuer, R L, et al.
Publicado: (2021)

Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2
por: Visschedijk, Marijn C., et al.
Publicado: (2016)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
por: Kanis, Shannon Linda, et al.
Publicado: (2021)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Comment on Szczubełek et al. Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients. Nutrients 2021, 13, 4112
por: van Lingen, Emilie, et al.
Publicado: (2022)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
por: Jansen, Fenna M, et al.
Publicado: (2023)

Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed
por: Loveikyte, Roberta, et al.
Publicado: (2022)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

IFIP-ICC vocabulary of information processing
por: Fédération Internationale pour le Traitement de l'Information. La Haye
Publicado: (1966)

Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
por: Proietti, Elisa, et al.
Publicado: (2022)

ICAAC/ICC 2015
por: McConnell, John
Publicado: (2015)

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
por: van der Valk, Mirthe E., et al.
Publicado: (2016)

The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum
por: Loveikyte, R., et al.
Publicado: (2023)

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021)

The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review
por: Paulides, Emma, et al.
Publicado: (2020)

Acute interstitial nephritis during rifampicin therapy can be a paradoxical response: a case report
por: van der Meulen, Jan, et al.
Publicado: (2009)

Differentiated ratings of perceived exertion in upper body exercise
por: Abonie, Ulric S., et al.
Publicado: (2023)

Pathophysiological Implications of Interstitial Cajal-like Cells (ICC-like) in Uterus: A Comparative Study with Gastrointestinal ICCs
por: López-Pingarrón, Laura, et al.
Publicado: (2023)

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature
por: Smeets, Fabiënne G M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kkf1sdt85boe7fgm1fiuucjtd2